concluded that only a few studies were including cardiac end points in their pattern. We subsequently highlight another major caveat of most ongoing clinical trials, which fail to incorporate any accurate information regarding radiationrelated cardiac hazard.
There is growing biological and clinical evidence that cardiac toxicity should be considered as the result of additive or supraadditive toxic effects, not as the consequence of a specific therapy [2] . Past experiences brought strong evidence that ionizing radiation may cause heart disease, and particularly so when provided concurrently with systemic cardiotoxic agents [3] . The toxicity data reported with adjuvant trastuzumab and/ or conventional chemotherapy agents could be amplified by previous exposure to other cardiotoxic agents, such as irradiation. Whereas the long-term effects of such sequential or concurrent association remain unknown, cardiac mortality from breast cancer treatments will develop decades later, while the patient is cured [4] .
Although recent irradiation modalities were found to facilitate sparing the heart and coronaries from irradiation, particularly for left-sided patients, those did not annihilate the risk for subsequent cardiotoxicity, which might be increased by concurrent chemotherapy or targeted agents [3] . A substantial amount of relevant information should be mandatory in further clinical assessments, including doses delivered to the coronaries or the left ventricle. Recently, the University of Michigan developed a cardiac atlas that could be incorporated as a useful predictive tool in studies assessing cardiac toxicity from new combinations [5] . Since most breast cancer patients receiving chemotherapy and/or targeted agents are likely to have also received adjuvant radiotherapy, including such dosimetric data could permit better defining the true cardiotoxicity of targeted anticancer therapies. 
